Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

New Label Mirrors Planned Parenthood’s Existing Protocols

New Label Means that Medication Abortion Can Once Again be Provided According to Evidence Based Medicine in All 50 States

WASHINGTON, DC --- Today, the U.S. Food and Drug Administration (FDA) approved a new label for Mifeprex (mifepristone), one of the medicines used in a medication abortion.  The new label updates the protocol for medication abortion so it reflects the most common evidence-based protocols recommended by Planned Parenthood, the World Health Organization, the American Medical Association, the American College of Obstetricians and Gynecologists and the Society for Family Planning.  The FDA’s approval of the new label is based on substantial evidence demonstrating that medication abortion is safe for virtually all women.

“First and foremost, this is another affirmation from the FDA that medication abortion is a safe and effective option to end an early pregnancy. Studies show medication abortion has a 99 percent safety record, and that medication abortion is up to 98 percent effective in ending an early pregnancy,” said Raegan McDonald-Mosley, Chief Medical Officer of Planned Parenthood Federation of America.  

Mifepristone, also known as medication abortion or “the abortion pill” (formerly known as RU-486), is an antiprogesterone drug that blocks receptors of progesterone, a key hormone in the establishment and maintenance of pregnancy.  Used in combination with a prostaglandin such as misoprostol, mifepristone induces abortion when administered in early pregnancy, providing women with an alternative to aspiration (suction or surgical) abortion.  A medication abortion is different than emergency contraception, or “the morning after pill,” which prevents a pregnancy from occurring.  

An overwhelming majority of women who choose mifepristone for medication abortion are satisfied with the method.  One study found that 97 percent of women would recommend the method to a friend.  Additionally, 91 percent of the women reported that they would choose the mifepristone regimen again if they had to have another abortion.

Until today, the regimen outlined on mifepristone’s final printing label approved by the FDA was based on clinical trials completed in the mid-1990s.  Numerous subsequent studies have demonstrated the safety and effectiveness of a regimen using a lower dosage of mifepristone that can also be used three weeks later in pregnancy,  through 70 days since a woman’s last menstrual period. This new regimen has been recognized by the American Medical Association and the American College of Obstetricians and Gynecologists as “superior” to the regimen on the previous FDA-approved label.

“Since Planned Parenthood’s medical standards are constantly-evolving with the latest clinical research findings, we have actually had the protocols approved today in place at Planned Parenthood for some time,” Dr. McDonald-Mosley continued.  “But given the restrictions on medication abortion enacted at the state level in recent years, updating the label to reflect best medical practice represents a significant step forward for science, for women, and for health care providers who want to give our patients the highest quality care.”

The benefit of this announcement will be most immediately felt by women and providers in Ohio, Texas and North Dakota --- states where laws are in effect requiring that medication abortion be provided according to the regimen outlined on mifepristone’s label (similar restrictions on medication abortion passed but have been blocked by court order in Arizona, Arkansas, and Oklahoma). While it is widely accepted standard medical practice for medicines to be used in different protocols than those upon which the FDA issues approval, these laws compelled health care providers to use an outdated, inferior and less effective regimen.

Setting aside other restrictive state laws that interfere with the doctor-patient relationship and the provision of abortion in these states, the FDA’s approval of the new Mifeprex label means that medication abortion can once again be provided everywhere in the U.S. in accordance with what research shows is safest and most effective.  However, the Arizona legislature is on the verge of amending state law to require that providers follow the regimen outlined on the old label for medication abortion, regardless of scientific evidence and the new FDA-approved label.


Planned Parenthood is the nation’s leading provider and advocate of high-quality, affordable health care for women, men, and young people, as well as the nation’s largest provider of sex education. With over 650 health centers across the country, Planned Parenthood organizations serve all patients with care and compassion, with respect and without judgment. Through health centers, programs in schools and communities, and online resources, Planned Parenthood is a trusted source of reliable health information that allows people to make informed health decisions. We do all this because we care passionately about helping people lead healthier lives.


Planned Parenthood Federation of America


Planned Parenthood Federation of America media office: 212-261-4433


March 30, 2016

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.



We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.



We use qualitative data to learn about your user experience and improve our products and services.